Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists01:23

Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists

Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Pharmacogenomics: Identification of New Drug Targets01:29

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...
Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase01:27

Pharmacogenetics of Phase II Enzymes: N-acetyltransferase, Thiopurine S-methyltransferase, UDP-glucuronosyltransferase

Phase II biotransformation reactions are essential for detoxifying and eliminating xenobiotics, including many pharmaceutical compounds. These reactions typically involve conjugation, the covalent attachment of polar endogenous groups such as glucuronic acid, sulfate, methyl, or acetyl moieties to functional groups introduced during Phase I metabolism. The resulting conjugates are more water-soluble, enabling efficient renal or biliary excretion.The major classes of Phase II enzymes include...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Genotype-Phenotype Relationships in Phenylalanine Hydroxylase Deficiency: Functional Annotation-Enhanced Analysis of 23,427 Individuals.

Genetics in medicine : official journal of the American College of Medical Genetics·2026
Same author

Integrating Functional Consequence Annotation With PAH Allelic Phenotype Values Refines Prediction of Tetrahydrobiopterin Responsiveness.

Journal of inherited metabolic disease·2026
Same author

Clinical and biochemical footprints of inherited cofactor disorders.

Molecular genetics and metabolism·2026
Same author

Clinical and biochemical footprints of inherited metabolic disorders: XIX. Hypoglycemia.

Molecular genetics and metabolism·2026
Same author

A Novel Multimodal LC-MS/MS Panel for the Comprehensive Diagnosis of Neurometabolic Disorders in CSF.

Journal of inherited metabolic disease·2026
Same author

Clinical and biochemical footprints of primary mitochondrial disorders: proposed nosology.

Molecular genetics and metabolism·2026

Related Experiment Video

Updated: May 14, 2026

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells
11:00

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells

Published on: October 17, 2025

Sepiapterin: From sapropterin to next-generation therapy.

Nenad Blau1

  • 1Divisions of Metabolism, University Children's Hospital, Zürich, Switzerland.

Molecular Genetics and Metabolism
|May 12, 2026
PubMed
Summary
This summary is machine-generated.

Oral sepiapterin effectively increases tetrahydrobiopterin (BH4) levels in healthy individuals and shows promise in treating phenylketonuria (PKU). Sepiapterin demonstrates superior efficacy compared to sapropterin in reducing blood phenylalanine levels in PKU patients.

Keywords:
BiomarkersDihydrobiopterinPhenylalaninePhenylketonuriaSepiapterinTetrahydrobiopterin

More Related Videos

A Step by Step Protocol for Subretinal Surgery in Rabbits
12:31

A Step by Step Protocol for Subretinal Surgery in Rabbits

Published on: September 13, 2016

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Related Experiment Videos

Last Updated: May 14, 2026

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells
11:00

3D Flipwell Engineering for Developing Asynchronous Systems for Toxicologic and Immunomodulatory Therapies in Bacterial, Gut, and Immune Cells

Published on: October 17, 2025

A Step by Step Protocol for Subretinal Surgery in Rabbits
12:31

A Step by Step Protocol for Subretinal Surgery in Rabbits

Published on: September 13, 2016

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System
07:04

Electroporation-Based Genetic Modification of Primary Human Pigment Epithelial Cells Using the Sleeping Beauty Transposon System

Published on: February 4, 2021

Area of Science:

  • Biochemistry
  • Pharmacology
  • Genetics

Background:

  • Tetrahydrobiopterin (BH4) is a crucial cofactor for enzymes like phenylalanine hydroxylase (PAH) and nitric oxide synthases.
  • BH4 homeostasis involves de novo synthesis, recycling, and salvage pathways, with sepiapterin serving as a key precursor.
  • 7,8-dihydrobiopterin (BH2) impacts BH4-dependent signaling and reflects pterin redox balance.

Purpose of the Study:

  • To review the biochemical and clinical understanding of BH4 homeostasis.
  • To evaluate sepiapterin as a precursor for BH4 and its therapeutic potential.
  • To compare the efficacy of sepiapterin and sapropterin in managing phenylketonuria (PKU).

Main Methods:

  • Integration of historical, chemical, biochemical, and clinical data on BH4.
  • Assessment of sepiapterin uptake and intracellular conversion to BH4.
  • Clinical trials (APHENITY and AMPLIPHY) evaluating sepiapterin's effect on blood phenylalanine levels in PKU patients.

Main Results:

  • Oral sepiapterin administration leads to significant systemic BH4 exposure and increased cerebrospinal fluid BH4 levels in healthy volunteers.
  • In PKU patients, sepiapterin significantly reduced blood phenylalanine levels.
  • Sepiapterin demonstrated greater efficacy than sapropterin in lowering phenylalanine levels in PKU.

Conclusions:

  • Sepiapterin is a promising therapeutic agent for BH4 deficiencies and PKU, potentially serving as a next-step therapy beyond sapropterin.
  • Biomarker studies quantifying BH4, BH2, and their ratio are essential for understanding BH4 homeostasis and treatment response.
  • Sepiapterin's mechanism involves cellular uptake and intracellular conversion, expanding BH4 pools effectively.